Business Context and Reporting Period
Company: Supernus Pharmaceuticals, Inc. (SUPN)
Filing Type: Form 8-K (Current Report)
Date of Report: February 28, 2023
Reporting Period: Fourth quarter and full year ended December 31, 2022
This filing serves as a notification that the Company issued a press release regarding its financial results for the fourth quarter and full year ended December 31, 2022. The detailed financial data is contained in Exhibit 99.1 (Press Release), which is incorporated by reference but not deemed "filed" for liability purposes under Section 18 of the Exchange Act.
Key Financial Metrics
Revenue, Profit, Cash Flow, Margins, Debt, and Liquidity: The provided text does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These figures are located in the referenced press release (Exhibit 99.1) and are not included in the body of this 8-K summary.
Material Changes
The filing does not detail specific material changes versus the prior comparable period within the text provided. It only confirms the issuance of results for the period ended December 31, 2022.
Guidance, Outlook, and Risks
- Management Commentary: The Company hosted a conference call on February 28, 2023, to present business and financial results. A webcast is archived on the Company's website.
- Forward-Looking Statements: The filing contains forward-looking statements regarding plans, strategies, and intentions. These are subject to risks and uncertainties.
- Risks and Contingencies: Risks include ordinary business operations, general economic conditions, and market competition. Specific risk factors are referenced in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2021.
- Unusual Items: No unusual items are described in the text of this filing.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for specific Q4 and full-year 2022 financial figures (revenue, net income, cash position).
- Access the archived webcast on www.supernus.com for management's detailed commentary on the results.
- Consult the Form 10-K for the fiscal year ended December 31, 2021, for a comprehensive list of risk factors referenced in this filing.
- Note that the information in this 8-K is "furnished" and not "filed" for liability purposes under Section 18 of the Exchange Act.